Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aims: DW1601, an oral fixed dose combination syrup composed of DW16011 and Pelargonium sidoides, was developed to enhance the symptom relief effect in patients with acute bronchitis. We evaluated the efficacy and safety of DW1601 compared to DW16011 or P. sidoides for treatment of acute bronchitis using a randomized, double-blind, placebocontrolled, multi-centre trial design.
Methods: A total of 204 patients with acute bronchitis was randomized 1:1:1 to receive DW1601 (n = 67), DW16011 (n = 70), or P. sidoides (n = 64) for 7 days. The primary outcome was efficacy of DW1601 compared to DW16011 or P. sidoides in reducing the total bronchitis severity score (BSS) at day 4 of treatment. Secondary endpoints were changes in total and symptomspecific BSS, response rate and patient satisfaction rate. Safety analysis was assessed at day 7.
Results: At 4 days after medication, decrease of total BSS from baseline was significantly greater in the DW1601 group than in the DW16011 group (-3.51 ± 0.18 vs. -2.65 ± 0.18, p = 0.001) or P. sidoides group (-3.56 ± 0.18 vs. -2.64 ± 0.19, p < 0.001). In addition, the BSS total score at day 7 and the BSS cough and sputum component scores at days 4 and 7 were significantly more improved with DW1601 treatment compared with the DW16011 group or P. sidoides group. Participants treated with DW1601 showed higher rates of response and satisfaction than control groups (response rate, DW1601, 100% vs. DW16011, 85.7% vs. P. sidoides, 85.9%; satisfaction rate, DW1601, 92.6% vs. DW16011, 82.9% vs. P. sidoides, 81.2%). Significant adverse events were not observed in the DW1601 group.
Conclusion: DW1601 is superior to DW16011 or P. sidoides in improving symptoms of acute bronchitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666245 | PMC |
| http://dx.doi.org/10.3904/kjim.2022.104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Value of thoracic ultrasound including focused cardiac ultrasound in daily practice of outpatient chest clinic.
Multidiscip Respir Med
September 2025
Department of Chest Diseases, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Background: Chest examination alone may be insufficient to declare cardiorespiratory diseases specially in its early stages and/or silent forms, also it is impractical for the CXR and cardiac consultation to be requested for every patient in the outpatient clinic, therefore involving the chest US and FoCUS (Focused Cardiac Ultra Sound) examination in the bedside practice of outpatient chest clinic may influence the clinical diagnosis and management plan.
Objective: To determine how the bedside thoracic US including FoCUS can alter the clinical diagnosis in patients who are clinically diagnosed as acute bronchitis in the outpatient chest clinic.
Subjects And Methods: This study was conducted at Chest outpatient clinic, Al-Azhar University in the period between January 2024 to March 2025.
A Multicenter, Open-Label Study to Assess the Safety of Nebulized Tissue Plasminogen Activator for the Acute Treatment of Pediatric Plastic Bronchitis: The PLATyPuS Trial.
Pharmacotherapy
September 2025
Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan Health System, Ann Arbor, Michigan, USA.
Introduction: Pediatric plastic bronchitis (PB) is a rare complication of surgically palliated congenital heart disease (CHD). Fibrin casts obstruct airways and can cause respiratory distress. There are no therapeutics approved by the United States Food and Drug Administration to treat PB, but inhaled tissue plasminogen activator (tPA) has been anecdotally used to relieve symptoms.
View Article and Find Full Text PDFPathologic Characterization of Highly Pathogenic H5N1 Avian Influenza Virus Infections in Wild Mammals in Alaska, USA.
J Wildl Dis
September 2025
Division of Wildlife Conservation, Alaska Dept of Fish and Game, 1300 College Road, Fairbanks, Alaska 99701, USA.
This report describes highly pathogenic avian influenza virus (HPAI) H5N1 infections in carnivores in Alaska, US between 2022 and 2024, including a black bear (Ursus americanus), a brown bear (Ursus arctos), and the first known report of HPAI in an ermine (Mustela ermina). The two bears were cubs, and the ermine was a young adult. The black bear and ermine were euthanized after demonstrating neurologic signs, including circling, blindness, ataxia, or seizures.
View Article and Find Full Text PDFPolypharmacy and non-returned off-island referral among residents of remote islands: a retrospective cohort study in Okinawa, Japan.
Rural Remote Health
August 2025
Department of Clinical Research and Quality Management, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Introduction: Deterioration of chronic conditions and serious acute illnesses are major factors preventing older individuals from remaining within their local communities, which may be significant burdens for islanders. The specific reasons and risk factors associated with non-returned off-island referrals remain insufficiently investigated. This study aims to describe cases of non-return after off-island referrals and to examine the relationship between polypharmacy and non-returned off-island referral among older residents regularly attending remote island clinics.
View Article and Find Full Text PDFTGF-β inhibitor SB431542 suppresses SARS-CoV-2 replication through multistep inhibition.
J Virol
August 2025
National Centre for Veterinary Type Cultures, ICAR-National Research Centre on Equines, Hisar, India.
Unlabelled: The coronavirus disease 2019 (COVID-19) pandemic highlighted the critical need for broad-spectrum antivirals with high resistance barriers. Here, we demonstrate that SB431542, a selective TGF-β receptor I (ALK5) inhibitor, exhibits potent antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through unprecedented multitargeted mechanisms. Through comprehensive , isothermal titration calorimetry, and analyses, we identified that SB431542 directly binds to SARS-CoV-2 ORF3a and disrupts its canonical function in inhibiting autophagosome-lysosome fusion.
View Article and Find Full Text PDF